Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
52 hedge funds and large institutions have $184M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 8 reducing their positions, and 5 closing their positions.
238% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 8
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
21% more funds holding
Funds holding: 43 → 52 (+9)
19% more capital invested
Capital invested by funds: $154M → $184M (+$30M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.15M |
| 2 |
WCM
Wildcat Capital Management
New York
|
+$5.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.16M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.81M |
| 5 |
Morgan Stanley
New York
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Partner Investment Management
San Francisco,
California
|
-$4.96M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$2.41M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.35M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$484K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$254K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | – | – | – |
|
52
Daiwa Securities Group
Tokyo,
Japan
| $2K | +$1.98K | +113 | New |
|
|
ACM
53
Asymmetry Capital Management
San Francisco,
California
| – | -$484K | -26,692 | Closed |
|
|
PCM
54
Prelude Capital Management
New York
| – | -$254K | -13,974 | Closed |
|
|
TCIM
55
TIAA CREF Investment Management
New York
| – | -$135K | -7,433 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$18K | -975 | Closed |
|
57
Parallax Volatility Advisers
San Francisco,
California
| – | -$14K | -756 | Closed |
|
SNNA Hedge Fund Activity: Q1 2018 in Review
52 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q1 2018, worth a combined $184M — up 19% from $154M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SNNA positions and 5 closed out — a net gain of 9 holders — while 27 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $7.15M. The largest seller was Partner Investment Management, cutting an estimated $4.96M.
- 52 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q1 2018, up from 43 in Q4 2017.
- Funds reported $184M of Sienna Biopharmaceuticals, Inc. stock for Q1 2018, up 19% quarter-over-quarter.
- 14 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q1 2018 and 5 closed out, a net change of +9 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q1 2018 was BlackRock, an estimated $7.15M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q1 2018 was Partner Investment Management, an estimated $4.96M sold.
Based on aggregated 13F filings for Q1 2018.